Multiple Myeloma

The European Commission approved subcutaneous daratumumab plus VRd for newly diagnosed multiple myeloma, regardless of transplant eligibility.

The top 5 OncLive videos of the week cover insights in multiple myeloma, AL amyloidosis, ovarian cancer, prostate cancer, breast cancer, and follicular lymphoma.

Orca-T boosts cGVHD-free survival in hematologic malignancies, cilta-cel continues to impress in CARTITUDE-4, and more.

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

MDC-CAR-BCMA001 may be a suitable construct for the treatment of BCMA-pretreated patients with triple-class refractory multiple myeloma or AL amyloidosis.

Ciltacabtagene autoleucel is the first CAR T-cell therapy to show significant OS benefit in multiple myeloma.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in multiple myeloma, HER2+ breast cancer, non¬–muscle-invasive bladder cancer, and ovarian cancer.

Jeffrey Zonder, MD, emphasizes the importance of identifying MGUS and evaluating nonspecific symptoms to improve the detection of multiple myeloma.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights advances in T-cell–redirecting therapies in the space.

During Multiple Myeloma Awareness Month, Joshua Richter, MD, highlights symptom recognition and precursor conditions for the malignancy.

Amrita Krishnan, MD, highlights key innovations in multiple myeloma, including GPRC5D-targeted agents and evolving strategies in T-cell–directed therapy.

Jeffrey Zonder, MD, discusses the need for increased awareness in multiple myeloma.

The top 5 OncLive videos of the week cover insights in gynecologic cancer, multiple myeloma, urothelial cancer, MPNs, and prostate cancer.

Alfred L. Garfall, MD, describes the inclusion criteria for a phase 2 study evaluating ide-cel as first-line maintenance in multiple myeloma.

P-BCMA-ALLO1 displayed high response rates and compelling safety in a heavily pretreated population of patients with relapsed/refractory multiple myeloma.

The top 5 OncLive videos of the week cover insights in colorectal cancer, myeloma, HER2+ breast cancer, and KRAS G12X+ pancreatic ductal adenocarcinoma.

Joshua Richter, MD, discusses the evolution of multiple myeloma treatment in recognition of Myeloma Awareness Month 2025.

Guenther Koehne, MD, discusses the roles of ASCT, CAR T-cell therapy, and bispecific antibodies in the treatment of patients with multiple myeloma.

Preclinical cytotoxicity was demonstrated with anti-CD38-CAR-gamma-delta T cells in multiple myeloma.

Marco Ruella, MD, discusses ways to develop accessible cancer treatments to more greatly benefit diverse populations of patients with multiple myeloma.